— Know what they know.
Not Investment Advice

MYMD NASDAQ

MyMD Pharmaceuticals, Inc.
1W: +5.7% 1M: +2.8% 3M: -21.3% 1Y: -94.5% 3Y: -98.9% 5Y: -99.7%
$1.81
Last traded 2024-08-19 — delisted
NASDAQ · Healthcare · Biotechnology · $4.3M mcap · 2M float · 2.96% daily turnover

Balance Sheet Trends

Total Assets
$18M +1.8% ▲
5Y CAGR: +18.0%
Total Liabilities
$5M +78.9% ▲
5Y CAGR: +20.9%
Shareholders Equity
$13M -13.1% ▼
5Y CAGR: +17.0%
Cash & Investments
$5M +1.8% ▲
5Y CAGR: -2.0%
Total Debt
$49K -65.5% ▼
Net Debt
-$3M -333.4% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2019FY2020FY2021FY2022FY2023
— Assets —
Cash$517K$148K$556K$749K$3M
Short-Term Investments$9M$0$11M$4M$2M
Cash & ST Investments$10M$148K$12M$5M$5M
Net Receivables$43K$0$0$0$0
Inventory$199K$0$0$0$0
Other Current Assets$629K$1K$1M$566K$893K
Total Current Assets$10M$150K$13M$5M$6M
Property, Plant & Equip.$34K$527K$149K$140K$47K
Goodwill & Intangibles$18K$0$10M$10M$10M
Long-Term Investments$115K$0$2M$2M$2M
Other Non-Current Assets$711K$0$0$2M$0
Total Non-Current Assets$574K$527K$12M$12M$12M
Total Assets$11M$677K$25M$18M$18M
— Liabilities —
Accounts Payable$599K$2M$868K$2M$3M
Short-Term Debt$15K$546K$53K$66K$49K
Deferred Revenue-$15-$2M$0$0$265K
Other Current Liabilities$916K$0$119K$347K$1M
Total Current Liabilities$2M$2M$1M$3M$5M
Long-Term Debt$990K$4M$96K$76K$0
Other Non-Current Liab.-$990K$0$30K$0$0
Total Non-Current Liabilities$990K$4M$126K$76K$101K
Total Liabilities$2M$6M$1M$3M$5M
— Equity —
Common Stock$129M$4K$102M$108M$2K
Retained Earnings-$120M-$49M-$79M-$94M-$102M
Accumulated OCI$18K-$145K-$102M-$145K-$2K
Total Stockholders Equity$9M-$5M$24M$15M$13M
Total Liabilities & Equity$11M$677K$25M$18M$18M
— Key Metrics —
Total Debt$1M$4M$149K$142K$49K
Net Debt$487K$4M-$407K-$607K-$3M
Total Investments$9M$0$13M$6M$4M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms